More than 700,000 Americans undergo LASIK each year, accepting a permanent trade: a laser vaporizes a thin layer of corneal tissue to bend light more accurately, and that tissue never grows back. A biomedical engineering group at the University of California, Irvine, has now demonstrated a fundamentally different approach. In a study published in ACS Biomaterials Science & Engineering, the team showed that brief electrical pulses delivered through a platinum contact lens can reshape the cornea of rabbit eyes, producing measurable changes in curvature without any cutting, ablation, or heat. The entire treatment takes roughly one minute.
The technique, called electromechanical reshaping (EMR), does not remove tissue at all. Instead, it exploits a quirk of collagen chemistry: when a controlled electrical current passes through the cornea, it generates tiny pH shifts near the electrode surface. Those shifts temporarily loosen the electrostatic bonds holding collagen fibrils in their rigid arrangement, making the tissue pliable enough to conform to the shape of the contact lens. Once the current stops and pH normalizes, the collagen stiffens in its new configuration.
Where the science stands as of mid-2026
The UC Irvine team, led by researchers in the Beckman Laser Institute, tested two electrochemical protocols on rabbit eyes: a constant-potential mode and a pulsed-potential mode. Both changed corneal curvature, but the pulsed approach gave finer control over the total electrical charge delivered to the tissue, and by extension, the degree of reshaping.
The biological mechanism did not originate in the eye. An earlier study by the same group showed that passing current through rabbit septal cartilage produced local pH gradients that softened collagen without thermal damage. Cartilage and cornea are both collagen-dense tissues, so the researchers adapted the principle, swapping needle electrodes for a shaped platinum contact lens that could mold the corneal surface.
A follow-on analysis using second-harmonic generation (SHG) microscopy, published in Experimental Eye Research, examined whether the electrical treatment scrambled the fine architecture of corneal collagen. It did not. The collagen fibrils retained their spacing and alignment, a critical finding because corneal transparency depends on that precise microstructure. Disorganized fibrils scatter light and cloud vision, so any reshaping method that wrecks the lattice is a nonstarter.
Taken together, the published data establish three things. First, short electrical treatments can produce statistically significant, directionally controlled curvature changes in an animal cornea. Second, the mechanism is consistent with reversible, pH-driven collagen softening rather than bulk heating or mechanical cutting. Third, at least immediately after treatment and at the microscopic level, the collagen organization that underpins clarity appears to survive the procedure.
What the studies have not answered
Every EMR result published so far comes from rabbit eyes. No human trial data or clinical trial registrations appear in the National Library of Medicine databases. That gap matters because rabbit corneas differ from human corneas in thickness, hydration, collagen crosslinking density, and wound-healing behavior. A curvature change that corrects one diopter in a rabbit eye will not necessarily produce the same refractive shift in a human eye with different geometry and biomechanics.
Durability is also unknown. The SHG analysis confirmed collagen organization shortly after treatment, but neither that paper nor the primary reshaping study reports what happens weeks or months later. Without long-term follow-up, there is no way to know whether the cornea gradually drifts back toward its original shape. If it does, EMR might be limited to temporary corrections unless protocols are refined to lock in the change.
Safety data remain thin. Endothelial cell counts, a standard benchmark in corneal research because the adult endothelium does not regenerate, have not been reported. Subtle cell loss might not cloud the cornea immediately but could compromise it over years. The studies also have not detailed effects on corneal nerves, which are densely packed in the anterior stroma and essential for tear production and surface sensation. Nerve disruption is one of the most common complaints after LASIK, so any successor technology will face pointed questions on this front.
The specific voltage levels, charge densities, and pulse frequencies that produced successful reshaping are described in the full-text methods of the ACS paper but do not appear in publicly available abstracts. That limits independent assessment of how much margin exists between the dose that softens collagen and the dose that could cause electrochemical tissue damage. Without a clearly mapped therapeutic window, outside groups cannot easily evaluate the robustness of the technique.
How EMR compares to existing alternatives
LASIK and photorefractive keratectomy (PRK) both use excimer lasers to permanently ablate corneal tissue. They are precise, well-studied, and backed by decades of outcomes data, but they are irreversible. A patient whose prescription continues to change after surgery has limited retreatment options because there is only so much cornea to remove.
Orthokeratology, or ortho-k, already reshapes the cornea without surgery by using rigid gas-permeable contact lenses worn overnight. The effect is temporary: stop wearing the lenses and the cornea returns to its original shape within days. Ortho-k works well for mild to moderate myopia but cannot correct higher prescriptions or astigmatism as effectively as laser procedures.
EMR sits in a conceptual space between these options. Like ortho-k, it uses a contact lens and avoids tissue removal. But unlike ortho-k, the reshaping is driven by an active electrochemical process rather than passive mechanical pressure, which could, in theory, produce more targeted and longer-lasting changes. And unlike LASIK, EMR does not destroy tissue, which raises the tantalizing possibility of repeatable, incremental corrections over time. That possibility is consistent with the published mechanism but has not been tested experimentally. Repeated exposure to electrical fields could introduce cumulative risks that no one has characterized yet.
Why caution still outweighs excitement
The distance between a successful rabbit experiment and a device an ophthalmologist can offer a patient is measured in years and regulatory milestones, not just scientific publications. Any device that delivers electrical current directly to the human cornea will require extensive preclinical safety testing, formal regulatory submissions (likely through the FDA’s premarket approval pathway for high-risk ophthalmic devices), and phased clinical trials before it reaches a clinic.
No public statements from the research team about a regulatory timeline or commercial development partner have appeared in indexed biomedical literature as of June 2026. Until formal clinical trial registrations surface, any projection about when EMR might be available to patients is speculation.
The most grounded takeaway right now is narrower than the headline suggests but still genuinely significant: corneal collagen can be reshaped through non-thermal electrochemical means, and that reshaping can occur without grossly disturbing the microscopic order that keeps the cornea transparent. Whether this laboratory finding evolves into a clinical tool will depend on careful dose mapping, rigorous long-term safety studies, and transparent reporting as the work moves, if it does, from animal models to human eyes.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
